Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy

[1]  A. Thrasher,et al.  Gene therapy for monogenic disorders of the bone marrow , 2015, British journal of haematology.

[2]  Volker Huppert,et al.  Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. , 2015, Cytotherapy.

[3]  Daniel G. Miller,et al.  VISA - Vector Integration Site Analysis server: a web-based server to rapidly identify retroviral integration sites from next-generation sequencing , 2015, BMC Bioinformatics.

[4]  S. Parmar,et al.  Umbilical cord blood graft engineering: challenges and opportunities , 2015, Bone Marrow Transplantation.

[5]  E. Seifried,et al.  Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies , 2015, Transfusion.

[6]  R. Orentas,et al.  Towards a commercial process for the manufacture of genetically modified T cells for therapy , 2015, Cancer Gene Therapy.

[7]  D. See,et al.  Gene Therapy Studies in a Canine Model of X-Linked Severe Combined Immunodeficiency , 2015 .

[8]  G. Sauvageau,et al.  Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal , 2014, Science.

[9]  D. Silbergeld,et al.  Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. , 2014, The Journal of clinical investigation.

[10]  T. Torgerson,et al.  Intravenous injection of a foamy virus vector to correct canine SCID-X1. , 2014, Blood.

[11]  Y. Ikeda,et al.  Lentiviral vectors: basic to translational. , 2012, The Biochemical journal.

[12]  F. Cosset,et al.  A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. , 2012, Blood.

[13]  S. Frantz.  Engineered T-cell therapy shows efficacy in blood cancer , 2011, Nature Biotechnology.

[14]  L. Naldini.  Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[15]  H. Kiem,et al.  Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. , 2010, The Journal of clinical investigation.

[16]  H. Kiem,et al.  Large animal models of hematopoietic stem cell gene therapy , 2010, Gene Therapy.

[17]  J. Segovia,et al.  Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. , 2010, Human gene therapy.

[18]  J. Wagner,et al.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector , 2010, Gene Therapy.

[19]  David A. Williams,et al.  Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. , 2008, Cancer research.

[20]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.

[21]  N. Naumann,et al.  Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy. , 2006, Blood.

[22]  J. Dick,et al.  Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. , 2004, Blood.

[23]  C. von Kalle,et al.  Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. , 2003, Blood.

[24]  G. Aguirre,et al.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  F. Cosset,et al.  Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. , 2002, Blood.

[26]  D. Haas,et al.  Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  D. Clapp,et al.  Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. , 1998, Blood.

[28]  J. Tisdale,et al.  Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. , 1998, Blood.

[29]  M. Kay,et al.  In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. , 1993, Science.

[30]  P. Felsburg,et al.  Gene therapy studies in a canine model of X-linked severe combined immunodeficiency. , 2015, Human gene therapy. Clinical development.

[31]  H. Kiem,et al.  High-throughput genomic mapping of vector integration sites in gene therapy studies. , 2014, Methods in molecular biology.

[32]  David A. Williams,et al.  Stem cell collection and gene transfer in Fanconi anemia. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Dick,et al.  Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. , 2000, Blood.